Home » FightingDrugFailure » Partner Sites » Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology (IKP) » Leading Scientists » Matthias Schwab

Prof. Dr. med. Matthias Schwab

Prof. Dr. Matthias Schwab

Professor and Chair of Clinical Pharmacology,
Head of the Dr. Margarete Fischer-Bosch-Institute
of Clinical Pharmacology, Stuttgart
and
Department of Clinical Pharmacology,
Institute of Experimental and Clinical Pharmacology and Toxicology,
University Hospital, Tübingen

Dr. Margarete Fischer-Bosch-Institut für Klinische Pharmakologie
Auerbachstrasse 112
70376 Stuttgart

Phone: +49 (0) 711 - 8101 3700
Fax: +49 (0) 711 - 859 295
e-mail: matthias.schwab(AT)ikp-stuttgart.de

Professional Activities

  • Civilian service as house officer and later as senior house officer at the Children’s Hospital, Nuernberg, Germany (Prof. Dr. H.Gröbe) (1990 - 1993)
  • Senior house officer at the University Hospital of Children and Adolescents, Friedrich-Alexander University of Erlangen-Nuernberg, Erlangen, Germany (Prof. Dr. C. Stehr) (1993 - 1995)
  • Fellow in clinical pharmacology at the Dr Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, Germany (Prof. Dr. M. Eichelbaum) (1995 - 2001)
  • Coordinator of the research focus „Pharmacogenetics“ at the Dr Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, Germany (Prof. Dr. M. Eichelbaum) (2000 – 2005)
  • Senior physician and Head of the Research Unit for Clinical Trials and Drug Information Centre at the Dr Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, Germany (Prof. Dr. M. Eichelbaum) (2001 - 2005)
  • Visiting Professor, St. Jude Children’s Research Hospital, Department of Pharmaceutical Sciences, Memphis, Tennessee, USA (Prof. W.E. Evans; Focus on “Pharmacogenomics”) (2005 - 2006)
  • Decline of professorship for Clinical Pharmacology, Medical University Innsbruck, Austria (2006)
  • Professor and Chair of Clinical Pharmacology (W3/C4), Eberhard Karl University Tuebingen, Germany and Head of the Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, and the Department of Clinical Pharmacology, University Hospital, Tuebingen (1/2007 – present)

Education

  • Study of medicine, Friedrich-Alexander University of Erlangen-Nürnberg (1983 -1990)
  • Doctor`s degree of medicine, Institute of Toxicology and Pharmacology, University Erlangen Nürnberg (Prof. Dr. R. Böcker und Prof. Dr. C. Estler). Title of thesis: "Impact of subchronic treatment of mice with nifedipin on hepatic cytochrom P-450 isoenzyme activities in comparison to enzyme activities in different species." (1991)
  • State Licence as medical doctor (1992)
  • Board certification: Paediatrics and Adolescent Medicine (1996)
  • Special qualification as emergency physician for newborns (acc to DÖGNPI), education for paediatric nephrology, additional certification in: Paediatric ultrasonography of the thyroid gland of head and neck, of the gastrointestinal tract and of female genitals, certification in addiction medicine in children and adolescents, certification in radiological diagnostics for thoracic organs, certification in basic psychosomatic medicine
  • Board certification: Clinical Pharmacology (2000)
  • Qualification as university lecturer (Habilitation) for "Clinical Pharmacology and Paediatric Pharmacology" at the Eberhard-Karls University Tuebingen (Prof. Dr. Osswald) Title: "Relevance of genetic polymorphisms of P-glycoprotein and thiopurine S-methyltransferase for development and therapy of inflammatory bowel disease" (2003)

Honours / Memberships

  • Scholarship according to the "Bayerischen Begabtenförderungsgesetz" (1983 - 1990)
  • Full member of the "Committee of Drug Safety" of the German Society of Child and Adolescent Medicine (Chair: Prof. Dr. Seyberth, Marburg) (1998 – present)
  • Member of the Research Committee at the Robert-Bosch Hospital, Stuttgart (1999 - 2005)
  • Full Member and Vice Chair of the Expert Group "Drugs for Children and Adolescents" according to AMG at the German Federal Institute of Drugs and Medicinal products (BfArM) (Re-Calls in 2006, 2009 and 2011)
  • Member of the Expert Group "HEXAL-initiative drugs for children" (2004 - 2010)
  • Member of the ethical committee of the Landesärztekammer Baden-Württemberg (2004 - present)
  • Friedrich Hartmut-Dost Award (2004)
  • Extraordinary member of the CPMP Pediatric Expert Group (PEG) of the EMEA in London (authorized by German Society of Child and Adolescent Medicine) (2001 - 2004)
  • Galenus von Pergamon Award (2005)
  • Chairman of the board of scientists at the Robert-Bosch Hospital/IKP, Stuttgart (2007 - present)
  • Member of the „Drug Commission of the German Medical Association (AkdÄ) (2007 - present)
  • Member of IUPHAR Division of Clinical Pharmacology - Sub-Committee Pharmacogenetics (2008 - present)Member of the medical executive board of the Robert Bosch Hospital, Stuttgart (2009 - present)
  • Member of the Chair of the Comprehensive Cancer Center (CCC) of the University Hospital, Tuebingen (2009 - present)
  • Full member of the American Society for Clinical Pharmacology and Therapeutics (ASCPT) (2010 -present)
  • Vice Chairman of the Natural and Medical Sciences Institute (NMI) in Reutlingen (non-profit public-law foundation) (2010 - present)
  • EACPT Key lecture “Personalized Medicine beyond Pharmacogenetics”, 16th World Congress on Basic and Clinical Pharmacology, Copenhagen, Denmark (2010)
  • Councillor for the European region in the "IUPHAR Drug Metabolism Section Executive Board" (2010 -2014)
  • Expert for pharmacogenetics in the Gendiagnostikkommission of the Federal Ministry of Health (2010 -2013)
  • Member of the Council of EACPT (European Association of Clinical Pharmacology and Therapy) (2010 –present )
  • Approval of the IKP (M. Schwab) as a training center for the area “drug information” by the "Landesapothekerkammer Baden Württemberg"
  • Member of the Executive Board of the IDM Foundation (Institute of Digital Medicine), Stuttgart (2011 -2013)
  • Member of the board of trustees of the IDM Foundation (Institute of Digital Medicine), Stuttgart (2013 - present)
  • Member of the Executive Committee of the EACPT (2011- 2015)
  • Member of the Committee for Research Strategy & Coordination – an advisory board of the University of Tuebingen (an initiative of the rector of the University) (2012 - 2014)
  • Full Member of the Academy of Science and Literature, Mainz, Germany (2012)
  • Chairman of the German Society of Clinical Pharmacology (2012-2015)
  • Member of Faculty of 1000 Prime, Section Pharmacogenomics (2012 - present)
  • Member in the Committee of Experts on Drug Prescription of the Federal Ministry of Health (2013 - 2017)
  • Member of the "Weiterbildungsausschuss für die Facharztkompetenz Klinische Pharmakologie" (training committee for qualification as medical specialist in clinical pharmacology) at the Bezirksärztekammer Nordwürttemberg (2013 - present)
  • Member of the Scientific Advisory Board of the Reference Institute for Bioanalytics (Foundation for Pathobiochemistry and Molecular Diagnostics, Bonn) (2014 - )
  • Member of the Board of Trustees of the European Health Foundation (EHF) (2013 -  )

    Editorial Boards / Editor

    • Editor in Chief of "Pharmacogenetics and Genomics" (from 2010)
    • Section Editor "Personalized Medicine and Therapeutics" of genome Medicine
    • Clinical Chemistry
    • Therapeutic Drug Monitoring
    • British Journal of Clinical Pharmacology
    • The Open Clinical Chemistry Journal
    • Journal of Personalised Medicine

    Book Editor

    • Schwab M, Kaschka WP, Spina E (eds.). Pharmacogenomics in Psychiatry. Advances in Biological Psychiatry. Vol. 25. Karger, 2010Seyberth WH, Rane A, Schwab M (eds.)
    • Seyberth WH, Rane A, Schwab M (eds.). Handbook of Experimental Pharmacology. Pediatric Clinical Pharmacology, 14. Auflage, Springer, 2011


    Publications: > 230


    Talks: > 300


    Main Research Interests

    • Pharmacogenomics / Epigenetics of drug metabolizing enzymes, drug transporters and nuclear receptors
    • Pharmacogenomics of anticancer and immunosuppressive drugs
    • Drug Interaction
    • Pediatric clinical pharmacology
    • Novel methodologies in genomic research and molecular diagnostics